Symptoms: unknown.
Treatment: symptomatic.
hypersensitivity to nifuroxazide, nitrofuran derivatives or other components of the drug,
fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose and isomaltase insufficiency (due to the presence of sucrose in the drug),
pregnancy,
children under 3 years of age.
It is not recommended to use concomitantly with drugs that cause the development of disulfiram-like reactions, drugs that inhibit the function of the central nervous system.
If the patient is taking other medications (including over-the-counter medications), before using Ersefuril® you should consult your doctor.
Solid gelatin capsules No. 1, consisting of a body and a cap of yellow color.
Capsule contents - yellow powder.
Allergic reactions (skin rashes, urticaria, Quincke's edema, anaphylactic shock).
If any of the side effects listed in the description worsen, or the patient notices any other side effects not listed in the description, you should inform your doctor.
Without a prescription.
In the treatment of diarrhea, rehydration therapy should be performed simultaneously with nifuroxazide therapy.
In the case of bacterial diarrhea with signs of systemic damage (deterioration of the general condition, fever, symptoms of intoxication or infection), you should consult a doctor to decide on the use of systemic antibacterial drugs. If you experience symptoms of hypersensitivity (shortness of breath, skin rash, itching), stop taking the drug. Drinking alcohol during treatment with nifuroxazide is prohibited.
Indication for patients with diabetes mellitus. One single dose (1 capsule) of Ersefuril® contains 72 mg of sucrose, which corresponds to 0.00072 XE. The maximum daily dose (4 caps.) contains 288 mg of sucrose, which corresponds to 0.0288 XE.
Influence on the ability to drive vehicles, mechanisms. The drug Ersefuril® it does not affect the ability to drive vehicles and mechanisms.
Acute bacterial diarrhea, occurring without deterioration of the general condition, increase in body temperature, intoxication.
Nifuroxazide is an antimicrobial agent derived from nitrofuran. It blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle, and a number of other biochemical processes in the microbial cell. Destroys the membrane of the microbial cell, reduces the production of toxins by microorganisms. Highly active in relation to Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp., Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.
Weakly sensitive to nifuroxazide: Citrobacter spp., Enterobacter cloacae and Proteus indologenes.
Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp.
He disrupts the balance of the intestinal microflora. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.
After oral administration, nifuroxazide is practically not absorbed from the digestive tract and has its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestine: 20% - unchanged, and the remaining amount of nifuroxazide-chemically altered.
At a temperature not exceeding 30 °C.
Keep out of reach of children.
Shelf life of the drug Ersefuril®5 лет.Do not use after the expiration date indicated on the package.
| Capsules | 1 caps. |
| active substance: | |
| nifuroxazide | 200 mg |
| excipients: corn starch, sucrose, magnesium stearate | |
| capsule: | |
| body: gelatin, titanium dioxide (E171), iron oxide yellow dye (E172) | |
| the lid: gelatin, titanium dioxide (E171), iron oxide yellow dye (E172) |
Capsules, 200 mg. 14 caps each in a PVC/aluminum foil blister. 1 or 2 bl. are placed in a cardboard pack.
In animal studies, nifuroxazide has not been shown to have a teratogenic effect. However, as a precautionary measure, taking nifuroxazide during pregnancy is not recommended (insufficient clinical experience of use during pregnancy).
During the lactation period, it is possible to continue breastfeeding in the case of a short course of treatment with the drug. You should consult your doctor.
Inside.
Children from 3 to 6 years old - 200 mg (1 capsule) 3 times a day (the interval between doses is 8 hours).
Children from 6 to 18 years old - 200 mg (1 capsule) 3-4 times a day (the interval between doses is 6-8 hours).
Adults - 200 mg (1 capsule) 4 times a day (the interval between doses is 6 hours).
Duration of treatment: 5-7 days, but no more than 7 days.
If there is no improvement within the first 3 days of taking it, you should consult a doctor.
The drug should be used only according to the method of use and in the doses specified in the description. If necessary, you should consult your doctor before using the drug.
A07AX03 Nifuroxazide
